375 related articles for article (PubMed ID: 8810132)
21. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
22. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
23. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
Min Y; Qiang F; Peng L; Zhu Z
Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
25. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
26. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
28. [Effect of Chai-ling-tang (Sairei-to) for methotrexate concentration degradation delay by methotrexate high-dose therapy].
Utsuki S; Oka H; Suzuki S; Sato S; Osawa S; Koizumi H; Miyajima Y; Fujii K
No Shinkei Geka; 2010 Feb; 38(2):133-7. PubMed ID: 20166525
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
[TBL] [Abstract][Full Text] [Related]
30. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of low-dose methotrexate in adult asthmatics.
Glynn-Barnhart AM; Erzurum SC; Leff JA; Martin RJ; Cochran JE; Cott GR; Szefler SJ
Pharmacotherapy; 1992; 12(5):383-90. PubMed ID: 1437699
[TBL] [Abstract][Full Text] [Related]
32. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats.
Park JM; Moon CH; Lee MG
Res Commun Mol Pathol Pharmacol; 1996 Sep; 93(3):353-62. PubMed ID: 8896046
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.
Evans WE; Abromowitch M; Crom WR; Relling MV; Bowman WP; Pui CH; Ochs J; Dodge R
NCI Monogr; 1987; (5):81-5. PubMed ID: 3481040
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia.
Lönnerholm G; Valsecchi MG; De Lorenzo P; Schrappe M; Hovi L; Campbell M; Mann G; Janka-Schaub G; Li CK; Stary J; Hann I; Pieters R;
Pediatr Blood Cancer; 2009 May; 52(5):596-601. PubMed ID: 19132729
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
37. Renal function and methotrexate clearance in children with newly diagnosed leukemia.
Murry DJ; Synold TW; Pui CH; Rodman JH
Pharmacotherapy; 1995; 15(2):144-9. PubMed ID: 7624260
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
40. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
